Graphenea Semiconductor, a leading graphene foundry company and partner in the Graphene Flagship's 2D Pilot Line project and Melexis, a global supplier of micro-electronic semiconductor solutions, announces a strategic collaboration to accelerate the development and evaluation of Melexis’ integrated GFET-on-CMOS platform for advanced biosensing.
Recent research on various biomarkers for major depressive disorder (MDD) provide an opportunity to develop biosensors that can overcome the challenges faced by conventional diagnostic tools, MUNASET researchers say.
2D-BioPAD and MUNASET at Graphene Week 2025: Showcasing Graphene-Based Biomedical Innovation
Emergence of graphene-based biosensors for improved treatment response prediction in major depressive disorder: a perspective.
At the crossroads of cutting-edge materials science and advanced biomedical engineering, Jack Maughan is building tools that could reshape how we treat and interact with the brain. A postdoctoral researcher with a background in nanoscience and tissue engineering, Jack is exploring how graphene-based microneedles can enable next-generation neural interfaces devices that could one day treat neurological disorders, restore movement, and even enhance human-machine communication.
Enabling EU-funded project collaboration for brain health R&I
RIA PULSE: 4 HORIZON EUROPE PROJECTS IN ACTION
Welcome to the world of two-dimensional (2D) materials- Materials so thin, just a few atoms thick, which makes them both exceptionally lightweight and highly versatile. Some of these materials, such as graphene, are incredible strong, flexible, excellent conductors of electricity, and have a large surface area.
PRESS RELEASE - Strong collaboration among clinical, academic and industrial partners brings Europe a step closer to cost-effective point-of-care diagnostics for Alzheimer’s Disease.
INBRAIN Neuroelectronics SL, has raised $50 million to develop its graphene-based neural technologies.
Joint Biomed Workshop during Graphene Week 2024 strengthens collaboration between 2D-BioPAD and MUNASET projects
Partners from the MUNASET project met to report their progress and set the objectives for upcoming work.
Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer and immune system disorders. However, there is a lack of tools for real-time activity analysis of disease-related protease biomarkers.
With a nearly €6 million budget, 2D-BioPAD will develop a diagnostic system for early Alzheimer's disease detection. This Horizon Europe Research and Innovation Action funded by the European Union, officially commenced on October 2023 and will last 48 months.